Guardant Health (GH) won Food and Drug Administration approval Wednesday for its newest cancer-analyzing blood test, sending the stock to a three-month high.
The approval comes several months ahead of expectations “and is likely to result in modest upward revenue revisions this year,” William Blair analyst Andrew Brackmann said in a report
The new test, dubbed Guardant360 Liquid CDx, has… Related news Analyzing Profit Zones For Walmart, Quanta Services And Guardant Health Ahead Of Earnings 2/12/2026 IBD’s Alexis Garcia and Ed Carson preview key upcoming earnings reports from Walmart, Guardant Health and Quanta Services. 2/12/2026 IBD’s Alexis Garcia and Ed Carson preview key upcoming earnings